NorthSea Therapeutics develops therapeutics for NASH and other metabolic, inflammatory and fibrotic diseases.
Total raised: $149.59M
Investors 5
| Date | Name | Website |
| - | BioGenerat... | biogenerat... |
| - | Forbion | forbion.co... |
| - | Ysios Capi... | ysioscapit... |
| - | Sofinnova ... | sofinnova.... |
| - | New Scienc... | newscience... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.12.2021 | Series C | $80M | - |
| 08.01.2020 | Series B | $40M | - |
| 13.12.2017 | Series A | $29.59M | New Scienc... |
Mentions in press and media 16
| Date | Title | Description |
| 13.01.2025 | Forbion promotes Dirk Kersten to Managing Partner and strengthens US team | • Dirk Kersten promoted to Managing Partner, further strengthening firm’s leadership • Jonathan McNeill, M.D. joins Forbion as Partner in the Boston office Naarden, The Netherlands – 13 January 2025 - Forbion, a leading global life sciences... |
| 21.02.2024 | NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) | • Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in IFALD • The study will enrol up to 36 adult subjects at multiple sites in North America • Study strengthens NST’s position as a multi-asset, clinical stage com... |
| 29.12.2021 | These are the 21 biggest funding rounds of 2021 in the Netherlands | Over the last decade, the startup ecosystem’s value in the Netherlands has been rising fast. With a competitive talent pool, a complicated yet connected economic structure, and a booming tech sector, the Netherlands has enough reasons to be... |
| 28.12.2021 | Top milestone of Amsterdam 2021: Startups that hit the headlines | Amsterdam as a startup ecosystem packs an increasingly big punch. Over the last decade, the overall value of the startup ecosystem has been rising fast in Amsterdam. There are multiple factors behind this rise. Located centrally, the Nether... |
| 21.12.2021 | Amsterdam-based NorthSea Therapeutics secures €70.84M to develop treatment for metabolic disorders | Amsterdam-based NorthSea Therapeutics (NST), a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics, announced that it has raised $80M (approx €70.84M) in its Series C round of funding. ... |
| 17.12.2021 | NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders | NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today announces the close of a USD 80 million Series C ... |
| 17.12.2021 | Ysios Capital lidera una inversión de $80M en Northsea Therapeutics. Acuden también Forbion, venBio, Novo Seeds, BGV, Sofinnova y New Science Ventures | 17/12/2021 Nota de prensa YSIOS CAPITAL LIDERA UNA INVERSIÓN DE $80 MILLONES EN NORTHSEA THERAPEUTICS. − Northsea Therapeutics (Ámsterdam, Países bajos), es una compañía biotecnológica especializada en el desarrollo de productos terapéut... |
| 17.12.2021 | NorthSea Therapeutics Completes $80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders | - |
| 17.12.2021 | NorthSea Therapeutics B.V. announced that it has received $80 million in funding from a group of investors | NorthSea Therapeutics B.V. announced that it has raised $80 million in a round of funding co-led by new investor Ysios Capital Partners, SGEIC, S.A.U. and Forbion Growth Opportunities Fund I, a fund managed by returning investor Forbion Cap... |
| 17.12.2021 | NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders | Amsterdam, The Netherlands, 17 December 2021 – NorthSea Therapeutics B.V., (‘NST’) a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, today an... |
Show more